AbbVie Drug Price Connection Touted by Chamber in Updated Suit

The US Chamber of Commerce took another swing at blocking the Medicare agency’s drug price negotiation program by filing an amended complaint Friday.

In the complaint, the business group made the case for its standing to challenge the Medicare drug negotiation program established by last year’s Inflation Reduction Act. The Chamber’s request to halt the program was denied last month.

In justifying its associational standing to file a lawsuit, the Chamber said it and other plaintiffs count AbbVie Inc. as a member. AbbVie, the Chamber said, manufactures the cancer treatment Imbruvica, which was one of the 10 drugs the ...